<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="truncate">
            <roleset id="Truncate.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="cause&#x09;&#x09;&#x09;// mutation //&#x0A;" />
                    <role n="1" descr="entity getting shorter &#x09;// gene products //&#x0A;" />
                    <role n="2" descr="entity removed&#x09;&#x09;// domains, exon, intron //&#x0A;" />
                    <role n="3" descr='break point &#x09;&#x09;/* related to prepositional phrase such as &quot;at&quot;, &quot;prior to&quot; */&#x0A;' />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0 is able to truncate six activation domains, while all mutations that are missing so far fall into the high-mobility DNA binding domain (HMG).</text>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Almost all A0 mutations (TSC1) are found as dramatically truncated protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Almost all A0 mutations (TSC1) are found to truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Almost all A0 mutations (TSC1) have dramatically truncated protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Almost all TSC1 mutations have truncated protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from COS transfected cells and a protein expressed bacteria containing the zinc fingers BCL6 and truncated can specifically bind to the DNA of the promoter/valuator region of HIV-1 U3.</text>
                    <arg n="1">a protein expressed bacteria</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a bacterially expressed protein that is probably truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria containing the zinc fingers BCL6 and has been shown to be strongly truncated may specifically bind to the DNA of the promoter/valuator region of HIV-1 U3.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria containing the zinc fingers BCL6 and that is observed as strongly truncated may specifically bind to the DNA of the HIV-1 promoter/use valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria is able to be strongly truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that can be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that is able to be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that is observed to be strongly truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that is observed to be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that is truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that was truncated and contained the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressed by bacteria that will be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressing bacteria has been strongly truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressing bacteria</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressing bacteria that can be strongly truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressing bacteria</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressing bacteria that may have been strongly truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressing bacteria</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressing bacteria that was strongly truncated and contained the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressing bacteria</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Electrophoretic mobility assays showed that the total length BCL6 protein extracted from transfected COS cells and a protein expressing bacteria that will be strongly truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the HIV-1 promoter/use-valuing region.</text>
                    <arg n="1">a protein expressing bacteria</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and can be significantly truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and has been truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that can be significantly truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancing U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that contains the BCL6 zinc fingers and may have been significantly truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that has been shown to be truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/best region of U3 of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that has been truncated and containing the BCL6 zinc fingers can specifically bind to the DNA in the promoter/best region of U3 of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is likely to be truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/best region of U3 of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein truncated the BCL6 zinc fingers and has been shown to be specifically bound to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from the infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and is likely to be truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from the infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and may have been truncated can specifically bind to the DNA in the promoter/best region of U3 of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Electrophoretic mobility change tests showed that the full-length BCL6 protein extracted from the infected body cells and a bacterially expressed protein that can be truncated and contains the BCL6 zinc fingers can specifically bind to the DNA from the promoter/enhancing U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and capable of being truncated can specifically bind to DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and is able to be significantly truncated can specifically bind to DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and observed that it will be truncated can specifically bind to the DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and that can be significantly truncated can specifically bind to DNA in the HIV-1 promoter/expander region.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and that can be truncated can specifically bind to DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and that is probably being significantly truncated may specifically bind to the DNA in the HIV-1 promoter/expander region.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and that was truncated can specifically bind to the DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and that will be significantly truncated can specifically bind to the DNA in the HIV-1 promoter/expander region.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and will be truncated can specifically bind to the DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein is able to be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein that can be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA in the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein that has been truncated and contains the zinc fingers BCL6 can specifically bind to the DNA in the promoter/better U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is notably truncated and contains the zinc fingers BCL6 can specifically bind to the DNA of the promoter/U3 expansion region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is probably truncated and contains the zinc fingers BCL6 can specifically bind to the DNA in the HIV-1 promoter/expander region.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein that may have been truncated and contains the zinc fingers BCL6 may specifically bind to the DNA of the promoter/use valuer region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein that proved to be truncated and contains the zinc fingers BCL6 can specifically bind to the DNA in the promoter/better U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Electrophoretic mobility tests showed that the total length BCL6 protein extracted from infected body cells and a protein expressed bacteria containing the zinc fingers BCL6 and is notably truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a protein expressed bacteria</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from infected body cells and a protein expressed by bacteria containing the BCL6 zinc fingers and likely to be truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from infected body cells and a protein expressed by bacteria that contains the BCL6 zinc fingers and that it can be strongly truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from infected body cells and a protein expressed by bacteria that contains the BCL6 zinc fingers and that it may have been truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from infected body cells and a protein expressed by bacteria that contains the BCL6 zinc fingers and that may have been strongly truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from infected body cells and a protein expressed by bacteria that proved to be strongly truncated and contains the BCL6 zinc fingers can specifically bind to the U3-region DNA.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from infected body cells and a protein that expresses bacteria that contains the BCL6 zinc fingers and that has been strongly truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein that expresses bacteria</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Electrophoric mobility tests showed that the total length of the BCL6 protein extracted from the infected body cells and a protein expressed by bacteria containing the BCL6 zinc fingers and that it was strongly truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Electrophretic mobility tests showed that the total length of the BCL6 protein extracted from the infected body cells and a protein expressed by bacteria containing the BCL6 zinc fingers and it has been shown to be truncated can specifically bind to the DNA of the HIV-1 U3 promoter/valuer region.</text>
                    <arg n="1">a protein expressed by bacteria</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>For the generation of this protein, it is likely that the receptor will be truncated before two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>For the generation of this protein, it is observed that the receptor is truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>For the generation of this protein, it is observed that the receptor is truncated before two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>For the generation of this protein, the receptor can be truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>For the generation of this protein, the receptor can be truncated before two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>For the generation of this protein, the receptor is able to be truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>For the generation of this protein, the receptor is able to be truncated before two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>For the generation of this protein, the receptor is likely to be truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>For the generation of this protein, the receptor is truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>For the generation of this protein, the receptor is truncated before two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>For the generation of this protein, the receptor may have been truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>For the generation of this protein, the receptor may have been truncated before two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>For the generation of this protein, the receptor was truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>For the generation of this protein, the receptor will be truncated before two consecutive proline residues (`PP-motif_) present at the junction between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>For the generation of this protein, the receptor will be truncated before two consecutive proline residues (`PP-motif_) present in the binding between domains 2 and 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>For the generation of this protein, the the receptor is thought to be truncated before the two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>For the generation of this protein, the the receptor was truncated before the two consecutive proline residues (`PP-motif_) present in the binding of domains 2 to 3 (figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>In particular, the Stat5a molecule in which C-terminal can be notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>In particular, the Stat5a molecule in which C-terminal has been truncated to amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>In particular, the Stat5a molecule in which C-terminal has the ability to be notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>In particular, the Stat5a molecule in which C-terminal is likely to be significantly truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>In particular, the Stat5a molecule in which C-terminal is notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>In particular, the Stat5a molecule in which C-terminal is probably significantly truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>In particular, the Stat5a molecule in which C-terminal will be notably truncated to amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>In particular, the Stat5a molecule, in which it is observed that C-terminal is notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>In particular, the molecule Stat5a in which C-terminal can be notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>In particular, the molecule Stat5a in which C-terminal has been notably truncated at amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations on amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>In particular, the molecule Stat5a in which C-terminal is notably truncated to amino acids 740 or 751 effectively blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>In particular, the molecule Stat5a in which C-terminal is observed to be notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In particular, the molecule Stat5a in which C-terminal will be truncated in amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations in amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>It has been shown that SOX9 shifts of frame change truncates its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shifts of frame change</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>It has been shown that the SOX9 shift of frame truncates to the its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift of frame</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>It has been shown that the protein is truncated by A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values have been biased by the methods used, and in sequenced areas, approximately 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>It has been shown that the protein is truncated through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%) by most changes, although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>It is observed that SOX9 shift motion frame actually truncates to its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift motion frame</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>It is observed that SOX9 shift motion frame actually truncates to six activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift motion frame</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>It is observed that SOX9 shift motion frame truncates its two activation domains, while all the counter-sense mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift motion frame</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>It is observed that the SOX9 shift motion frame truncates the its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift motion frame</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Merchshift SOX9 may truncate six activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Merchshift SOX9 mutations actually truncated its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Merchshift SOX9 mutations can actually truncate its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Merchshift SOX9 mutations can truncate its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Merchshift SOX9 mutations has the ability to actually truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>Merchshift SOX9 mutations has the ability to truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>Merchshift SOX9 mutations have the probability of actually truncating its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Merchshift SOX9 mutations have the probability of truncating its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Merchshift SOX9 mutations have truncated its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Merchshift SOX9 mutations is able to actually truncate its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Merchshift SOX9 mutations is able to truncate its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>Merchshift SOX9 mutations is likely to actually truncate its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Merchshift SOX9 mutations is likely to truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Merchshift SOX9 mutations may have truncated its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Merchshift SOX9 mutations may have truncated its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Merchshift SOX9 mutations truncated its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Merchshift SOX9 mutations will actually truncate its two activation domains, while all incorrect-sense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Merchshift SOX9 mutations will truncate its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Merchshift SOX9 mutations, as our data show, is likely to truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Merchshift SOX9 mutations, as our data show, it is likely that its two activation domains is actually truncated, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Merchshift SOX9 mutations, as shown by our data, actually truncated its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Merchshift SOX9 mutations, as shown by our data, are able to truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Merchshift SOX9 mutations, as shown by our data, are able to truncate its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Merchshift SOX9 mutations, as shown by our data, can truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Merchshift SOX9 mutations, as shown by our data, can truncate its two activation domains, while all incorrect-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Merchshift SOX9 mutations, as shown by our data, has been shown to truncate its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Merchshift SOX9 mutations, as shown by our data, has shown that it actually truncates its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Merchshift SOX9 mutations, as shown by our data, have the ability to truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Merchshift SOX9 mutations, as shown by our data, have the probability of actually truncating its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Merchshift SOX9 mutations, as shown by our data, have the probability of truncating its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Merchshift SOX9 mutations, as shown by our data, have truncated its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>Merchshift SOX9 mutations, as shown by our data, is observed to actually truncate its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>Merchshift SOX9 mutations, as shown by our data, is observed to truncate its two activation domains, while all counter-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>Merchshift SOX9 mutations, as shown by our data, may have truncated its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>Merchshift SOX9 mutations, as shown by our data, will actually truncate its two activation domains, while all missense mutations reported to date are in the high-mobility group DNA-binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>Merchshift SOX9 mutations, as shown by our data, will truncate its two activation domains, while all common-sense mutations reported to date are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">Merchshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>Most changes have been found to truncate the protein through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were unfounded or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>Most of the alterations found were the truncation the protein through A0 (senseless mutations (32%), insertions or deletions (29.6%) or truncate alterations (6.2%), although the values were biased by the methods used, and in sequenced areas, about 50% of all mutations were absent or on table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>Practically all A0 mutations (TSC1) are able to dramatically truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>Practically all A0 mutations (TSC1) are able to truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Practically all A0 mutations (TSC1) can truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>Practically all A0 mutations (TSC1) have the ability to dramatically truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>Practically all A0 mutations (TSC1) have the ability to truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>Practically all A0 mutations (TSC1) may dramatically truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>Practically all A0 mutations (TSC1) may have dramatically truncated protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>Practically all A0 mutations (TSC1) may have truncated protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Practically all A0 mutations (TSC1) truncated dramatically protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Practically all A0 mutations (TSC1) truncated protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Practically all A0 mutations (TSC1) were predicted to dramatically truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Practically all A0 mutations (TSC1) will dramatically truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Practically all A0 mutations (TSC1) will truncate protein product.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Practically all TSC1 mutations are able to dramatically truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Practically all TSC1 mutations are able to truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Practically all TSC1 mutations can dramatically truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Practically all TSC1 mutations can truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Practically all TSC1 mutations dramatically truncated the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Practically all TSC1 mutations have been predicted to dramatically truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Practically all TSC1 mutations have been predicted to truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Practically all TSC1 mutations have dramatically truncated the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Practically all TSC1 mutations have the ability to dramatically truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Practically all TSC1 mutations have the ability to truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Practically all TSC1 mutations have truncated the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Practically all TSC1 mutations may have dramatically truncated the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Practically all TSC1 mutations may have truncated the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Practically all TSC1 mutations truncated the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Practically all TSC1 mutations were predicted to truncate protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Practically all TSC1 mutations will dramatically truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Practically all mutations TSC1 will truncate the protein product.</text>
                    <arg n="0">TSC1</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which are genetically designed to truncate or replace the A1 sectors (poly(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which are genetically modified to replace or truncate A1 sectors (poly(C)) produced conflicting data on the role of the polio sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which are probably genetic engineering to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which have been genetically modified to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which may be genetically modified to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which may be genetically modified to truncate or replace the A1 sectors (poly(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which may have been genetically designed to truncate or replace the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which may have been genetically modified to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and Mengo virus, and variants of these viruses, which were genetically designed to truncate or replace the A1 sectors (poly(C)) produced conflicting data on the role of the polio sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which are able to be genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which are able to be genetically modified to truncate or replacing poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which are genetically designed to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which are genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which are likely to be genetic engineering to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which can be genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which can be genetically modified to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which have been genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which may have been genetically designed to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which may have been genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>Previous studies using the Encephalomyocarditis Virus Type EMCV and the Mengo virus, and variants of these viruses, which were genetically designed to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>Previous studies using the Encephalomyocarditis Virus type EMCV and Mengo virus, and variants of these viruses, which are probably genetic engineering to truncate or replace the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>Previous studies using the Encephalomyocarditis Virus type EMCV and the Mengo virus, and variants of these viruses, which are likely to be genetic engineering to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ) which will be genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), observed that genetic engineering is able to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), observed that they are genetically engineers to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), which are observed as genetic engineering to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), which are observed as genetic engineering to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), which have been shown to be genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), which have been shown to be genetically modified to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these virulence.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses ), which were genetically designed to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses) which will be genetically designed to truncate or replace poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses, because they are able to be genetically modified to replace or truncate poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these virulence.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses, because they are able to be genetically modified to truncate or replacing poly(C) sectors produced conflicting data on the role of the poly(C) sector in the virulence of these virulence.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses, have been shown to be genetically modified to replace or truncate poly(C) sectors) produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>Previous studies using the Encephalomyocarditis virus type EMCV and the Mengo virus, and variants of these viruses, have been shown to be genetically modified to truncate or replace poly(C) sectors) produced conflicting data on the role of the poly(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">poly(C) sectors</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, as they are able to be genetically modified to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the polio sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, as they are able to be genetically modified to truncate or replace the A1 sectors (poly(C)) produced conflicting data on the role of the polio sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, have been shown to be genetically modified to truncate or replace sectors Poly(C) and produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">sectors Poly(C)</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, have been shown to replace or truncate sectors Poly(C) to produce conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                    <arg n="1">sectors Poly(C)</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, noted that genetic engineering is capable of replacing or truncating the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, observed that they are genetically modified engineers to truncate or replace the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which are observed as genetic engineering to replace or truncate the poly(C) sectors, produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which are observed as genetic engineering to truncate or replace the A1 sectors (poli(C)) produced conflicting data on the role of the polio sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which have been genetically modified to truncate or replace the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which have been shown to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which were genetically designed to truncate or replace the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which will be genetically designed to truncate or replace the A1 sectors (poly(C)) produced conflicting data on the role of the polio sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>Previous studies using the encephalomiocarditis virus type EMCV and Mengo virus, and variants of these viruses, which will be genetically modified to replace or truncate the A1 sectors (poli(C)) produced conflicting data on the role of the poli(C) sector in the virulence of these viruses.</text>
                    <arg n="0">EMCV</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>SOX9 shift frame changes, as shown by our data, can truncate its two activation domains, while all remaining mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift frame changes</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>SOX9 shift frame changes, as shown by our data, truncated its two activation domains, while all remaining mutations reported so far were in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift frame changes</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>SOX9 shift of frame has been shown to truncate to its two activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shift of frame</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>SOX9 shifts of frame change has been shown to truncate its two activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">SOX9 shifts of frame change</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>Specifically, the Stat5a molecule in which C-terminal can be notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>Specifically, the Stat5a molecule in which C-terminal can be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>Specifically, the Stat5a molecule in which C-terminal has been shown to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>Specifically, the Stat5a molecule in which C-terminal has the ability to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>Specifically, the Stat5a molecule in which C-terminal has the ability to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>Specifically, the Stat5a molecule in which C-terminal is able to be notably truncated to amino acids 740 or 751 blocked the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>Specifically, the Stat5a molecule in which C-terminal is able to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas for amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>Specifically, the Stat5a molecule in which C-terminal is able to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>Specifically, the Stat5a molecule in which C-terminal is likely to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>Specifically, the Stat5a molecule in which C-terminal is truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>Specifically, the Stat5a molecule in which C-terminal may have been notably truncated at amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations on amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>Specifically, the Stat5a molecule in which C-terminal may have been notably truncated in amino acids 740 or 751 blocked the induction of both CIS and OSM, while C-terminal truncations in the amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>Specifically, the Stat5a molecule in which C-terminal may have been truncated to amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>Specifically, the Stat5a molecule in which C-terminal may have been truncated to amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>Specifically, the Stat5a molecule in which C-terminal will probably be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>Specifically, the Stat5a molecule in which C-terminus has the ability to be truncated with emphasis on amino acids 740 or 751 truncated the induction of both CIS and OSM, while C-terminal truncas in the amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminus</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>Specifically, the Stat5a molecule in which C-terminus is able to be truncated with amino acids 740 or 751 truncated the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminus</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>Specifically, the Stat5a molecule in which C-terminus was truncated into amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations in amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminus</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>Specifically, the Stat5a molecule in which C-terminus will be strongly truncated into amino acids 740 or 751 blocked the induction of both CIS and OSM, while C-terminal truncas in amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminus</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>Specifically, the Stat5a molecule in which C-terminus will be truncated into amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations in amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminus</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>Specifically, the Stat5a molecule in which it was demonstrated that C-terminal was notably truncated to amino acids 740 or 751 blocked the induction of both SIC and SHO, while C-terminal truncas to amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>Specifically, the Stat5a molecule where C-terminal is truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncas to amino acids 762 or 773 have no effect on the induction of both genes.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>Specifically, the molecule Stat5a in which C-terminal can be notably truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>Specifically, the molecule Stat5a in which C-terminal can be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>Specifically, the molecule Stat5a in which C-terminal has been shown to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>Specifically, the molecule Stat5a in which C-terminal is observed to be truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>Specifically, the molecule Stat5a in which C-terminal is truncated to amino acids 740 or 751 blocks the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>Specifically, the molecule Stat5a in which C-terminal was strongly truncated in amino acids 740 or 751 blocked the induction of both CIS and OSM, while C-terminal truncations in amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>Specifically, the molecule Stat5a in which it has been shown that C-terminal was notably truncated to amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, while C-terminal truncations to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the molecule Stat5a</arg>
                    <arg n="2">C-terminal</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>Stat5a proteins truncated by C-terminal was shown to be notably truncated in amino acids 762 or 773 and had no effect on the induction of both genes.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminal</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>Stat5a proteins truncated by C-terminal was shown to be notably truncated to amino acids 762 or 773 did not have an effect on the induction of both genes.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminal</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>Stat5a proteins truncated by C-terminally has been shown to be notably truncated to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>Stat5a proteins truncated by C-terminally probably truncated to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>Stat5a proteins truncated by C-terminally that are likely to be truncated to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>Stat5a proteins truncated by C-terminally that are observed to be significantly truncated in amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>Stat5a proteins truncated by C-terminally that are truncated truncated to amino acids 762 or 773 have no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>Stat5a proteins truncated by C-terminally that have been notably truncated to amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>Stat5a proteins truncated by C-terminally that have been truncated to amino acids 762 or 773 have had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>Stat5a proteins truncated by C-terminally was observed to be notably truncated at amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>Stat5a proteins truncated by C-terminally was shown to be notably truncated at amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>Stat5a proteins truncated by C-terminally were probably notably truncated at amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>Stat5a proteins truncated by C-terminally which will be notably truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>Stat5a truncated proteins C that are able to be truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>Stat5a truncated proteins C that are able to be truncated with emphasis on amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>Stat5a truncated proteins C that are notably truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>Stat5a truncated proteins C that are truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>Stat5a truncated proteins C that can be truncated into amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>Stat5a truncated proteins C that can be truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="264">
                    <text>Stat5a truncated proteins C that may be especially truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="265">
                    <text>Stat5a truncated proteins C that may be notably truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="266">
                    <text>Stat5a truncated proteins C that may have been truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="267">
                    <text>Stat5a truncated proteins C that were notably truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>Stat5a truncated proteins C that were truncated into amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>Stat5a truncated proteins C that were truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>Stat5a truncated proteins C that will be notably truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>Stat5a truncated proteins C that will be truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>Stat5a truncated proteins C was shown to be truncated in amino acids 762 or 773 and had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>Stat5a truncated proteins by C that were observed to be notably truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins by C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>Stat5a truncated proteins by C was observed to be strongly truncated in amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Stat5a truncated proteins by C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>State 5th C truncated proteins that can be truncated with an emphasis on amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">State 5th C truncated proteins</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>Strat5a proteins truncated by C-terminal was probably truncated to amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminal</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>Strat5a proteins truncated by C-terminally that are notably truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>Strat5a proteins truncated by C-terminally that can be truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>Strat5a proteins truncated by C-terminally that could have been notably truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>Strat5a proteins truncated by C-terminally that could have been truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>Strat5a proteins truncated by C-terminally that may be notably truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>Strat5a proteins truncated by C-terminally that truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>Strat5a proteins truncated by C-terminally that were truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="284">
                    <text>Strat5a proteins truncated by C-terminally that were truncated to amino acids 762 or 773 had no effect on the induction of both genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="285">
                    <text>Strat5a proteins truncated by C-terminally which were notably truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a proteins truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="286">
                    <text>Strat5a truncated by C-terminally probably truncated to amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="287">
                    <text>Strat5a truncated by C-terminally proteins that are susceptible to be truncated to amino acids 762 or 773 has no effect on the induction of either of the two genes.</text>
                    <arg n="1">Strat5a truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="288">
                    <text>Strat5a truncated by C-terminally proteins that are truncated to amino acids 762 or 773 has no effect on the induction of either of the two genes.</text>
                    <arg n="1">Strat5a truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="289">
                    <text>Strat5a truncated by C-terminally proteins that are truncated truncated to amino acids 762 or 773 has no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="290">
                    <text>Strat5a truncated by C-terminally proteins that can be truncated to amino acids 762 or 773 has no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a truncated by C-terminally</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="291">
                    <text>Strat5a truncated proteins by C which are likely to be truncated with amino acids 762 or 773 had no effect on the induction of any of the two genes.</text>
                    <arg n="1">Strat5a truncated proteins by C</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EGRAM" no="292">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and can be truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="293">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and has been notably truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="294">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and is likely to be significantly truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="295">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and is notably truncated can specifically bind to the DNA in the promoter/enhancing U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="296">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and observed that it will be truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="297">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and that was truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="298">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and truncated can specifically bind to the DNA in the promoter/best region of U3 HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="299">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and will be significantly truncated can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="300">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and will be truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="301">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that can be truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="302">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that contained the BCL6 zinc fingers and was notably truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="303">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that contains the BCL6 zinc fingers and is capable of being significantly truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="304">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that contains the BCL6 zinc fingers and is capable of being truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="305">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that has been notably truncated and containing the BCL6 zinc fingers can specifically bind to the DNA in the promoter/best region of U3 of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="306">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that has been shown to be notably truncated and containing the BCL6 zinc fingers can specifically bind to the DNA from the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="307">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is likely to be notably truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="308">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is notably truncated and contains the BCL6 zinc fingers can specifically bind to the DNA from the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="309">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is observed to be notably truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="310">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is observed to be truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="311">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that is truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="312">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that may have been notably truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancing U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="313">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that may have been truncated and contains the BCL6 zinc fingers can specifically bind to the DNA from the promoter/enhancing U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="314">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that was notably truncated and contained the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="315">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that was truncated and contained the BCL6 zinc fingers can specifically bind to the DNA from the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="316">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that will be notably truncated and contains the BCL6 zinc fingers can specifically bind to the DNA from the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="317">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein that will be truncated and contains the BCL6 zinc fingers can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="318">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein truncated the BCL6 zinc fingers and has been shown to be specifically bound to the DNA in the promoter/enhancement region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="319">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from infected body cells and a bacterially expressed protein truncated the BCL6 zinc fingers and is observed to be specifically bound to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="320">
                    <text>Tests for changing electrophoretic mobility showed that the full-length BCL6 protein extracted from the infected body cells and a bacterially expressed protein containing the BCL6 zinc fingers and can be significantly truncated can specifically bind to the DNA in the promoter/enhancement U3 region of HIV-1.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="321">
                    <text>The electrophoretic mobility change tests showed that the total length BCL6 protein extracted from infected body cells and a bacterially expressed protein containing the zinc fingers BCL6 and has been truncated can specifically bind to the DNA in the HIV-1 promoter/expander region.</text>
                    <arg n="1">a bacterially expressed protein</arg>
                </example>
                <example src="EGRAM" no="322">
                    <text>The resulting putative protein maintained the region encoding the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR was truncated and the BMP-1 potential was not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="323">
                    <text>The resulting putative protein maintained the region encoding the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR were probably truncated and the BMP-1 potential was not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="324">
                    <text>The resulting putative protein retained the coding region of the structural and functional elements of amine oxidase, but the second and fourth SRCR domains are truncated and the potential separation site of BMP-1 is not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="325">
                    <text>The resulting putative protein retained the coding region of the structural and functional elements of amine oxidase, but the second and fourth SRCR domains can be truncated and the potential for segmentation of BMP-1 is not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="326">
                    <text>The resulting putative protein retained the coding region of the structural and functional elements of amine oxidase, but the second and fourth SRCR domains would be truncated and the potential segmentation site of BMP-1 was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="327">
                    <text>The resulting putative protein retained the coding region of the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR are truncated and the potential cleavage site of BMP-1 is not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="328">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of amine oxidase but the second and fourth SRCR domains has been shown to be truncated and the potential BMP-1 has not been present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="329">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of amine oxidase but the second and fourth SRCR domains is truncated and the potential BMP-1 is not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="330">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of amine oxidase, but it is observed that the second and fourth SRCR domains was truncated and the potential BMP-1 was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="331">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of amine oxidase, but the second and fourth SRCR domains could have been truncated and the potential BMP-1 is not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="332">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of amine oxidase, but the second and fourth SRCR domains have been truncated and the potential BMP-1 was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="333">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of the amine oxidase but the second and fourth SRCR domains were able to be truncated and the potential BMP-1 was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="334">
                    <text>The resulting putative protein retained the region by encoding the structural and functional elements of the amine oxidase but the second and fourth SRCR domains were probably truncated and the potential BMP-1 was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="335">
                    <text>The resulting putative protein retained the region encoding the structural and functional elements of amine oxidase, but it was observed that the second and fourth domains of SRCR was truncated and the BMP-1 potential was not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="336">
                    <text>The resulting putative protein retained the region encoding the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR could be truncated and the BMP-1 potential was not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="337">
                    <text>The resulting putative protein retained the region encoding the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR could have been truncated and the BMP-1 potential is not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="338">
                    <text>The resulting putative protein retained the region encoding the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR were able to be truncated and the BMP-1 potential was not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="339">
                    <text>The resulting putative protein retained the region encoding the structural and functional elements of amine oxidase, but the second and fourth domains of SRCR would be truncated and the BMP-1 potential was not present.</text>
                    <arg n="2">the second and fourth domains of SRCR</arg>
                </example>
                <example src="EGRAM" no="340">
                    <text>The resulting putative protein truncated the coding region of the structural and functional elements of amine oxidase, but the second and fourth SRCR domains has been shown and the potential division site of BMP-1 was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="EGRAM" no="341">
                    <text>The role of A1 N-terminus (M.MspI ), 2-hydroxy-5-nitrobenzyl bromide (HNBB) has been demonstrated to be used to truncate A1 (M.MspI) between waste 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">waste 34 and 35</arg>
                </example>
                <example src="EGRAM" no="342">
                    <text>Therefore, to generate a soluble fragment comparable to IC1-2D/190, PVR can also be truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="343">
                    <text>Therefore, to generate a soluble fragment comparable to IC1-2D/190, PVR is also truncated before PP-reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP-reason</arg>
                </example>
                <example src="EGRAM" no="344">
                    <text>Thus, to generate a soluble fragment comparable to CI1-2D/190, PVR can also be truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="345">
                    <text>Thus, to generate a soluble fragment comparable to CI1-2D/190, PVR may have been truncated before the PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP reason</arg>
                </example>
                <example src="EGRAM" no="346">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR has also been truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="347">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR is also able to be truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="348">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR is also likely to be truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="349">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR is also observed to truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="350">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR is also truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="351">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR may have been truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="352">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR was also truncated before PP-reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP-reason</arg>
                </example>
                <example src="EGRAM" no="353">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR will also be truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="354">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, PVR will also be truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="355">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, it has been shown that PVR is truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="356">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, it is also observed that PVR is truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="357">
                    <text>Thus, to generate a soluble fragment comparable to IC1-2D/190, it was demonstrated that PVR is truncated before PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP-motif</arg>
                </example>
                <example src="EGRAM" no="358">
                    <text>Thus, to truncated a soluble fragment comparable to IC1-2D/190, PVR is also liable to truncation before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="359">
                    <text>To assess the role of A1 N-term (M.MspI), 2-hydroxy-5-nitrobenzyl bromide (HNBB) is able to truncate A1 (M.MspI) between residence 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">residence 34 and 35</arg>
                </example>
                <example src="EGRAM" no="360">
                    <text>To assess the role of the N-terminal of M.MspI , 2-hydroxy-5-nitrobenzyl bromide (HNBB) will be used to truncate A1 (M.MspI) between residus 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residus 34 and 35</arg>
                </example>
                <example src="EGRAM" no="361">
                    <text>To assess the role of the N-terminal of M.MspI, 2-hydroxy-5-nitrobenzyl bromide (HNBB) can be used to truncate M.MspI between residus 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residus 34 and 35</arg>
                </example>
                <example src="EGRAM" no="362">
                    <text>To assess the role of the N-terminal of M.MspI, 2-hydroxy-5-nitrobenzyl bromide (HNBB) is found to be used to truncate M.MspI between residus 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residus 34 and 35</arg>
                </example>
                <example src="EGRAM" no="363">
                    <text>To assess the role of the N-terminal of M.MspI, 2-hydroxy-5-nitrobenzyl bromide (HNBB) is likely to be used to truncate M.MspI between residus 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residus 34 and 35</arg>
                </example>
                <example src="EGRAM" no="364">
                    <text>To assess the role of the N-terminal of M.MspI, 2-hydroxy-5-nitrobenzyl bromide (HNBB) is observed to be used to truncate M.MspI between residus 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residus 34 and 35</arg>
                </example>
                <example src="EGRAM" no="365">
                    <text>To assess the role of the N-terminal of M.MspI, 2-hydroxy-5-nitrobenzyl bromide (HNBB) may have been used to truncate M.MspI between residus 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residus 34 and 35</arg>
                </example>
                <example src="EGRAM" no="366">
                    <text>To evaluate the role of A1 N-term (M.MspI ), 2-hydroxy-5-nitrobenzyl bromide (HNBB) is observed that A1 (M.MspI) is used to truncate A1 (M.MspI) between waste 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">waste 34 and 35</arg>
                </example>
                <example src="EGRAM" no="367">
                    <text>To evaluate the role of A1 N-term (M.MspI ), 2-hydroxy-5-nitrobenzyl bromide (HNBB) will be used to truncate A1 (M.MspI) between residence 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">residence 34 and 35</arg>
                </example>
                <example src="EGRAM" no="368">
                    <text>To evaluate the role of A1 N-term (M.MspI), 2-hydroxy-5-nitrobenzyl bromide (HNBB) can be used to truncate A1 (M.MspI) between residence 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">residence 34 and 35</arg>
                </example>
                <example src="EGRAM" no="369">
                    <text>To evaluate the role of A1 N-terminal (M. MspI), 2-hydroxy-5-nitrobenzyl bromide (HNBB) may have been used to truncate A1 (M. MspI) between residue 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">residue 34 and 35</arg>
                </example>
                <example src="EGRAM" no="370">
                    <text>To evaluate the role of A1 N-terminal (M.MspI), 2-hydroxy-5-nitrobenzyl bromide (HNBB) is likely to be used to truncate A1 (M.MspI) between residue 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">residue 34 and 35</arg>
                </example>
                <example src="EGRAM" no="371">
                    <text>To evaluate the role of A1 N-terminal (M.MspI), 2-hydroxy-5-nitrobenzyl bromide (HNBB) is used to truncate A1 (M.MspI) between residue 34 and 35 to evaluate the role of A1 N-terminal (M.MspI), 2-hydroxy-5-nitrobenzyl bromide (HNBB) is used to trunca</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="3">residue 34 and 35</arg>
                </example>
                <example src="EGRAM" no="372">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR can be truncated before PP-reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP-reason</arg>
                </example>
                <example src="EGRAM" no="373">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR can therefore be truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="374">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR is likely to be truncated before the PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP reason</arg>
                </example>
                <example src="EGRAM" no="375">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR it may have been truncated before the PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP reason</arg>
                </example>
                <example src="EGRAM" no="376">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR may have been truncated before the PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP reason</arg>
                </example>
                <example src="EGRAM" no="377">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR was truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="378">
                    <text>To generate a soluble fragment comparable to CI1-2D/190, PVR will be truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="379">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR can be truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="380">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR has been shown to truncated before PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP-motif</arg>
                </example>
                <example src="EGRAM" no="381">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR has been truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="382">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR is likely to be truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="383">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR is therefore able to be truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="384">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR is therefore able to be truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="385">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR is therefore truncated before the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EGRAM" no="386">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR is truncated, therefore, before the PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP reason</arg>
                </example>
                <example src="EGRAM" no="387">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, PVR was truncated before the PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP reason</arg>
                </example>
                <example src="EGRAM" no="388">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, it is observed, therefore, that PVR is truncated before P motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">P motif</arg>
                </example>
                <example src="EGRAM" no="389">
                    <text>To generate a soluble fragment comparable to IC1-2D/190, it is observed, therefore, that PVR is truncated before PP reason.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">PP reason</arg>
                </example>
                <example src="EGRAM" no="390">
                    <text>To generate this protein, it has been shown that the receptor is truncated before two consecutive proline residues (`PP-motif_) present in the 2&#x13;3 (Figure 1) domain binding.</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="391">
                    <text>To generate this protein, the receptor is thought to be truncated before two consecutive proline residues (`PP-motif_) present in the 2&#x13;3 (Figure 1) domain binding.</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="EGRAM" no="392">
                    <text>To truncate the titin gene, we use a gene orientation approach so that the kinase domain and other downstream kinase domains are not expressed.</text>
                    <arg n="0">a gene orientation approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
                <example src="EGRAM" no="393">
                    <text>To truncate the titin gene, we used a gene orientation approach so that the kinase domain and other domains of descending flow kinase are not expressed.</text>
                    <arg n="0">a gene orientation approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
                <example src="EGRAM" no="394">
                    <text>Two of these variants result in A0 isoforms (altered post-synaptic density level 95 (PSD95) having the ability to dramatically truncate protein.</text>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="395">
                    <text>Two of these variants result in A0 isoforms (altered post-synaptic density level 95 (PSD95) having the ability to truncate protein.</text>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="396">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that are able to dramatically truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="397">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that are observed to dramatically truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="398">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that are observed to truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="399">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that are susceptible to dramatically truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="400">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that are susceptible to truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="401">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that have the ability to truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="402">
                    <text>Two of these variants result in altered post-synaptic density level 95 (PSD95) isoforms that will dramatically truncate protein.</text>
                    <arg n="0">altered post-synaptic density level 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="403">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that are able to truncate protein.</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="404">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that are able to truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="405">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that are known to truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="406">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that can truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="407">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that could dramatically truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="408">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that could truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="409">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that has been shown to dramatically truncate protein.</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="410">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that has been shown to dramatically truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="411">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that have been shown to truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="412">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that have truncated the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="413">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms which will truncate the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="414">
                    <text>Two of these variants result in altered the post-synaptic density level 95 (PSD95) isoformes which dramatically truncates protein.</text>
                    <arg n="0">altered the post-synaptic density level 95 (PSD95) isoformes</arg>
                    <arg n="1">protein</arg>
                </example>
                <example src="EGRAM" no="415">
                    <text>Two of these variants result in altered the postsynaptic density 95 (PSD95) isoforms truncated the protein .</text>
                    <arg n="0">altered the postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="416">
                    <text>Two of these variants result in altered the postsynaptic density 95 (PSD95) isoforms which dramatically truncated the protein.</text>
                    <arg n="0">altered the postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="417">
                    <text>Two of these variants result in alternate postsynaptic density 95 (PSD95) isoforms that have dramatically truncated the protein.</text>
                    <arg n="0">alternate postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="418">
                    <text>Two of these variants result in alternated postsynaptic density 95 (PSD95) isoforms that are known to dramatically truncate the protein .</text>
                    <arg n="0">alternated postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="419">
                    <text>Two of these variants result in alternated postsynaptic density 95 (PSD95) isoforms that can dramatically truncate the protein .</text>
                    <arg n="0">alternated postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="420">
                    <text>Two of these variants result in alternated postsynaptic density 95 (PSD95) isoforms that have the ability to dramatically truncate the protein.</text>
                    <arg n="0">alternated postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="421">
                    <text>Two of these variants result in alternated postsynaptic density 95 (PSD95) isoforms that may have dramatically truncated the protein.</text>
                    <arg n="0">alternated postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="422">
                    <text>Two of these variants result in alternated postsynaptic density 95 (PSD95) isoforms that may have truncated the protein .</text>
                    <arg n="0">alternated postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="423">
                    <text>Two of these variants truncate in altered postsynaptic density 95 (PSD95) isoforms that are observed truncating the protein .</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="424">
                    <text>We found a gene orientation approach to truncate the titin gene so that the kinase domain and other domains downstream of kinase would not be expressed.</text>
                    <arg n="0">a gene orientation approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
                <example src="EGRAM" no="425">
                    <text>We found a genetic direction approach to truncate the the titin gene so that the kinase domain and other kinase domains downstream were not expressed.</text>
                    <arg n="0">a genetic direction approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
                <example src="EGRAM" no="426">
                    <text>We use a gene orientation approach to truncate the titin gene so that the kinase domain and other downstream kinase domains are not expressed.</text>
                    <arg n="0">a gene orientation approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
                <example src="EGRAM" no="427">
                    <text>We used a gene orientation approach to truncate the titin gene so that the kinase domain and other domains of the descending flow kinase are not expressed.</text>
                    <arg n="0">a gene orientation approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
                <example src="EGRAM" no="428">
                    <text>frameshift SOX9 has the ability to truncate six activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="429">
                    <text>frameshift SOX9 is likely to truncating its two activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="430">
                    <text>frameshift SOX9 mutations actually truncated both activation domains while all the missing mutations reported so far were in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">both activation domains</arg>
                </example>
                <example src="EGRAM" no="431">
                    <text>frameshift SOX9 mutations can truncate both activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">both activation domains</arg>
                </example>
                <example src="EGRAM" no="432">
                    <text>frameshift SOX9 mutations is likely to truncate both activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">both activation domains</arg>
                </example>
                <example src="EGRAM" no="433">
                    <text>frameshift SOX9 mutations is likely to truncating its two activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="434">
                    <text>frameshift SOX9 mutations may have truncated six activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="435">
                    <text>frameshift SOX9 mutations may truncate both activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">both activation domains</arg>
                </example>
                <example src="EGRAM" no="436">
                    <text>frameshift SOX9 mutations may truncate six activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="437">
                    <text>frameshift SOX9 mutations truncated both activation domains, while all the missing mutations reported so far were in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">both activation domains</arg>
                </example>
                <example src="EGRAM" no="438">
                    <text>frameshift SOX9 mutations truncated six activation domains, while all the missing mutations reported so far were in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="439">
                    <text>frameshift SOX9 mutations will truncate both activation domains, while all the missing mutations reported so far fall within the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">both activation domains</arg>
                </example>
                <example src="EGRAM" no="440">
                    <text>frameshift SOX9 mutations, as our data show, are observed to truncate their two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">their two activation domains</arg>
                </example>
                <example src="EGRAM" no="441">
                    <text>frameshift SOX9 mutations, as our data show, can truncate its two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="442">
                    <text>frameshift SOX9 mutations, as our data show, has the ability to truncate its two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="443">
                    <text>frameshift SOX9 mutations, as our data show, have the probability of truncating their two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">their two activation domains</arg>
                </example>
                <example src="EGRAM" no="444">
                    <text>frameshift SOX9 mutations, as our data show, may have truncated its two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="445">
                    <text>frameshift SOX9 mutations, as our data show, truncated its two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="446">
                    <text>frameshift SOX9 mutations, as our data show, truncated their two activation domains, while all the absent mutations reported so far were in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">their two activation domains</arg>
                </example>
                <example src="EGRAM" no="447">
                    <text>frameshift SOX9 mutations, as our data show, will truncate six activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="448">
                    <text>frameshift SOX9 mutations, as our data, are susceptible to truncate six activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="449">
                    <text>frameshift SOX9 mutations, as our data, can truncate their two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">their two activation domains</arg>
                </example>
                <example src="EGRAM" no="450">
                    <text>frameshift SOX9 mutations, as our data, may truncate six activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="451">
                    <text>frameshift SOX9 mutations, as shown by our data, has shown to truncate their two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9 mutations</arg>
                    <arg n="2">their two activation domains</arg>
                </example>
                <example src="EGRAM" no="452">
                    <text>frameshift SOX9, as our data show, has the probability of truncating its two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="453">
                    <text>frameshift SOX9, as our data, has the ability to truncate six activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="454">
                    <text>frameshift SOX9, as shown by our data, has shown to truncate its two activation domains, while all the absent mutations reported so far are in the high mobility group DNA binding domain (HMG).</text>
                    <arg n="0">frameshift SOX9</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="455">
                    <text>merchshift SOX9 mutations is likely to truncate six activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">merchshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="456">
                    <text>merchshift SOX9 mutations may have truncated six activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">merchshift SOX9 mutations</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="457">
                    <text>of SOX9 frame change, as our data show, A2 truncated (its two activation domains), while all remaining mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">of SOX9</arg>
                </example>
                <example src="EGRAM" no="458">
                    <text>of SOX9 frame change, as shown in our data, is observed to truncate six activation domains, while all the reported absent mutations are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">of SOX9</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="459">
                    <text>of SOX9 frame change, as shown in our data, truncated the two activation domains, while all remaining mutations reported so far were in the high-mobility DNA binding domain (HMG).</text>
                    <arg n="0">of SOX9</arg>
                    <arg n="2">the two activation domains</arg>
                </example>
                <example src="EGRAM" no="460">
                    <text>of SOX9 frame change, like our data, is able to truncate six activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">of SOX9</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="461">
                    <text>soX9 shift frame changes, like our data, are able to truncate six activation domains, while all the missing mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">soX9 shift frame changes</arg>
                    <arg n="2">six activation domains</arg>
                </example>
                <example src="EGRAM" no="462">
                    <text>soX9 shift frame changes, such as our data, can truncate its two activation domains, while all remaining mutations reported so far are in the high-mobility group DNA binding domain (HMG).</text>
                    <arg n="0">soX9 shift frame changes</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="EGRAM" no="463">
                    <text>the protein can be truncated by A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="464">
                    <text>the protein can be truncated by A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most of the alterations, although the values were biased by the methods used, and in sequenced areas approximately 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="465">
                    <text>the protein can be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%), although the values were biased by the methods used, and in sequenced areas approximately 50% of all mutations were devoid of reasoning or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="466">
                    <text>the protein can be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%), although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were in the opposite direction or in charts.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="467">
                    <text>the protein can be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were opposite directions or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="468">
                    <text>the protein can be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although the figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were unreasoned or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="469">
                    <text>the protein has been shown to be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although the figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were unreasoned or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="470">
                    <text>the protein is likely to be truncated by A0 (non-sense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values have been biased by the methods used, and in sequenced areas, approximately 50% of all mutations were in the opposite direction or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="471">
                    <text>the protein is likely to be truncated by most changes through A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%), although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="472">
                    <text>the protein is likely to be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%), although the values were biased by the methods used, and in sequential areas, about 50% of all mutations were absent or on table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="473">
                    <text>the protein is likely to be truncated through A0 (no-sense mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%) by most changes, although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were opposite directions or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="474">
                    <text>the protein is observed to be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were unfounded or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="475">
                    <text>the protein is observed to be truncated through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%) by most changes, although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="476">
                    <text>the protein is predicted to be truncated by A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="477">
                    <text>the protein is predicted to be truncated by A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values have been biased by the methods used, and in sequenced areas, approximately 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="478">
                    <text>the protein is predicted to be truncated by most changes through A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%), although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="479">
                    <text>the protein is predicted to be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="480">
                    <text>the protein is truncated by A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values have been biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="481">
                    <text>the protein is truncated by most changes through A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%), although the values have been biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="482">
                    <text>the protein is truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were unfounded or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="483">
                    <text>the protein is truncated through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%) by most changes, although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="484">
                    <text>the protein may have been truncated by A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="485">
                    <text>the protein may have been truncated by A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most of the alterations, although the values were biased by the methods used, and in sequenced areas approximately 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="486">
                    <text>the protein may have been truncated by most changes through A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%), although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="487">
                    <text>the protein may have been truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were unfounded or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="488">
                    <text>the protein was truncated by A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="489">
                    <text>the protein was truncated by A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most of the alterations, although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="490">
                    <text>the protein was truncated by most changes through A0 (no-sense mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were opposite directions or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="491">
                    <text>the protein was truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%), although the values were biased by the methods used, and in sequenced areas approximately 50% of all mutations were devoid of reasoning or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="492">
                    <text>the protein was truncated by most changes through A0 (slower mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%), although the values were biased by the methods used, and in sequenced areas, approximately 50% of all mutations were in the opposite direction or in charts.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="493">
                    <text>the protein was truncated by most of the changes through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%), although the values were biased by the methods used, and in sequenced areas approximately 50% of all mutations were unfounded or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="494">
                    <text>the protein will be truncated by A0 (nonsense mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) by most alterations, although the values have been biased by the methods used, and in sequenced areas, approximately 50% of all mutations were absent or in table.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="495">
                    <text>the protein will be truncated by A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing alterations (6.2%) for most of the alterations, although the values have been biased by the methods used, and in sequenced areas approximately 50% of all mutations were senseless or framed.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="496">
                    <text>the protein will be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%) or splicing changes (6.2%), although the values have been biased by the methods used, and in sequenced areas approximately 50% of all mutations were in the opposite direction or in tables.</text>
                    <arg n="1">the protein</arg>
                </example>
                <example src="EGRAM" no="497">
                    <text>the protein will be truncated by most changes through A0 (senseless mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although figures were biased by the methods used, and, in sequenced areas, about 50% of all mutations were opposite directions or in frames.</text>
                    <arg n="1">the protein</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
